Literature DB >> 30001520

Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine.

Lynda Coughlan1, Peter Palese2.   

Abstract

Influenza viruses are important pathogens which pose an ongoing threat to public health due to their ability to mutate and evade immunity elicited by prior infection or vaccination. Their evolutionary diversity is facilitated by the plasticity of the antigenically variable head domain of the major surface glycoprotein, hemagglutinin (HA), which tolerates the accumulation of extensive mutations. To date, vaccines have focused on eliciting largely strain-specific immune responses toward the HA head. However, novel universal influenza vaccines aim to refocus immunity toward the immunosubdominant but conserved influenza virus HA stalk domain. Such vaccines could provide heterologous protection against diverse influenza viruses.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30001520     DOI: 10.1016/j.chom.2018.06.016

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  36 in total

Review 1.  VH1-69 antiviral broadly neutralizing antibodies: genetics, structures, and relevance to rational vaccine design.

Authors:  Fang Chen; Netanel Tzarum; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2019-03-16       Impact factor: 7.090

2.  Novel Small Molecule Targeting the Hemagglutinin Stalk of Influenza Viruses.

Authors:  Jin Il Kim; Sangmoo Lee; Gong Yeal Lee; Sehee Park; Joon-Yong Bae; Jun Heo; Hong-Youb Kim; Seok-Hun Woo; Hae Un Lee; Chung Am Ahn; Hye Jin Bang; Hyun Soo Ju; Kiwon Ok; Youngjoo Byun; Dae-Jin Cho; Jae Soo Shin; Dong-Yeon Kim; Mee Sook Park; Man-Seong Park
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

3.  Pre-existing immunity to influenza virus hemagglutinin stalk might drive selection for antibody-escape mutant viruses in a human challenge model.

Authors:  Jae-Keun Park; Yongli Xiao; Mitchell D Ramuta; Luz Angela Rosas; Sharon Fong; Alexis M Matthews; Ashley D Freeman; Monica A Gouzoulis; Natalia A Batchenkova; Xingdong Yang; Kelsey Scherler; Li Qi; Susan Reed; Rani Athota; Lindsay Czajkowski; Alison Han; David M Morens; Kathie-Anne Walters; Matthew J Memoli; John C Kash; Jeffery K Taubenberger
Journal:  Nat Med       Date:  2020-06-29       Impact factor: 53.440

Review 4.  The Multifaceted B Cell Response to Influenza Virus.

Authors:  Jonathan H Lam; Nicole Baumgarth
Journal:  J Immunol       Date:  2019-01-15       Impact factor: 5.422

Review 5.  Host Factors Impact Vaccine Efficacy: Implications for Seasonal and Universal Influenza Vaccine Programs.

Authors:  Santosh Dhakal; Sabra L Klein
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

6.  A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice.

Authors:  Carly M Bliss; Alec W Freyn; Tom G Caniels; Victor H Leyva-Grado; Raffael Nachbagauer; Weina Sun; Gene S Tan; Virginia L Gillespie; Meagan McMahon; Florian Krammer; Adrian V S Hill; Peter Palese; Lynda Coughlan
Journal:  Mol Ther       Date:  2022-01-07       Impact factor: 12.910

7.  Murine Cross-Reactive Nonneutralizing Polyclonal IgG1 Antibodies Induced by Influenza Vaccine Inhibit the Cross-Protective Effect of IgG2 against Heterologous Virus in Mice.

Authors:  Meito Shibuya; Taiki Aoshi; Etsushi Kuroda; Yasuo Yoshioka
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

8.  Original Antigenic Sin: Friend or Foe in Developing a Broadly Cross-Reactive Vaccine to Influenza?

Authors:  Priyadharshini Devarajan; Susan L Swain
Journal:  Cell Host Microbe       Date:  2019-03-13       Impact factor: 21.023

9.  The Interaction of Influenza A NS1 and Cellular TRBP Protein Modulates the Function of RNA Interference Machinery.

Authors:  Qi Wang; Jiaxin Wang; Yan Xu; Zhe Li; Binbin Wang; Yang Li
Journal:  Front Microbiol       Date:  2022-04-26       Impact factor: 5.640

Review 10.  Factors Which Contribute to the Immunogenicity of Non-replicating Adenoviral Vectored Vaccines.

Authors:  Lynda Coughlan
Journal:  Front Immunol       Date:  2020-05-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.